» Articles » PMID: 36754883

The Gut Microbiota Pathway Mechanisms of Diabetes

Overview
Journal AMB Express
Date 2023 Feb 8
PMID 36754883
Authors
Affiliations
Soon will be listed here.
Abstract

The contribution of dysbiotic gut microbiota configuration is essential when making reference to the metabolic disorders by increasing energy. It is important to understand that the gut microbiota induced metabolic disease mechanisms and inflammations. Thus it is imperative to have an insight into the state of all chronic subclinical inflammations influencing disease outcomes. However, from the emerging studies, there still exist inconsistencies in the findings of such studies. While making the best out of the reasons for inconsistencies of the findings, this review is designed to make a clear spell out as to the inconsistence of gut microbiota with respect to diabetes. It considered gut-virome alterations and diabetes and gut-bacteriome-gut-virome-alterations and diabetes as confounding factors. The review further explained some study design strategies that will spontaneously eliminate any potential confounding factors to lead to a more evidence based diabetic-gut microbiota medicine. Lipopolysaccharide (LPS) pro-inflammatory, metabolic endotoxemia and diet/gut microbiota insulin-resistance and low-grade systemic inflammation induced by gut microbiota can trigger pro-inflammatory cytokines in insulin-resistance, consequently, leading to the diabetic condition. While diet influences the gut microbiota, the consequences are mainly the constant high levels of pro-inflammatory cytokines in the circulatory system. Of recent, dietary natural products have been shown to be anti-diabetic. The effects of resveratrol on the gut showed an improved lipid profile, anti-inflammatory properties and ameliorated the endotoxemia, tight junction and glucose intolerance.

Citing Articles

Therapeutic Strategies to Modulate Gut Microbial Health: Approaches for Chronic Metabolic Disorder Management.

Rondanelli M, Borromeo S, Cavioni A, Gasparri C, Gattone I, Genovese E Metabolites. 2025; 15(2).

PMID: 39997751 PMC: 11857149. DOI: 10.3390/metabo15020127.


Global bibliometric analysis of traditional Chinese medicine regulating gut microbiota in the treatment of diabetes from 2004 to 2024.

Liang J, Lin X, Liao X, Chen X, Zhou Y, Zhang L Front Pharmacol. 2025; 16:1533984.

PMID: 39917613 PMC: 11799270. DOI: 10.3389/fphar.2025.1533984.


Bacteriophages and their potential for treatment of metabolic diseases.

Deng Y, Jiang S, Duan H, Shao H, Duan Y J Diabetes. 2024; 16(11):e70024.

PMID: 39582431 PMC: 11586638. DOI: 10.1111/1753-0407.70024.


Gut microbial metabolic signatures in diabetes mellitus and potential preventive and therapeutic applications.

Garcia-Gutierrez E, OMahony A, Dos Santos R, Marroqui L, Cotter P Gut Microbes. 2024; 16(1):2401654.

PMID: 39420751 PMC: 11492678. DOI: 10.1080/19490976.2024.2401654.


Updated Progress on Polysaccharides with Anti-Diabetic Effects through the Regulation of Gut Microbiota: Sources, Mechanisms, and Structure-Activity Relationships.

Zhang X, Wang J, Zhang T, Li S, Liu J, Li M Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675416 PMC: 11053653. DOI: 10.3390/ph17040456.


References
1.
Wang S, Yong H, He X . Multi-omics: Opportunities for research on mechanism of type 2 diabetes mellitus. World J Diabetes. 2021; 12(7):1070-1080. PMC: 8311486. DOI: 10.4239/wjd.v12.i7.1070. View

2.
Ze X, Duncan S, Louis P, Flint H . Ruminococcus bromii is a keystone species for the degradation of resistant starch in the human colon. ISME J. 2012; 6(8):1535-43. PMC: 3400402. DOI: 10.1038/ismej.2012.4. View

3.
Li B, Xu X, Gan R, Sun Q, Meng J, Shang A . Targeting Gut Microbiota for the Prevention and Management of Diabetes Mellitus by Dietary Natural Products. Foods. 2019; 8(10). PMC: 6835620. DOI: 10.3390/foods8100440. View

4.
Chu Y, Sun S, Huang Y, Gao Q, Xie X, Wang P . Metagenomic analysis revealed the potential role of gut microbiome in gout. NPJ Biofilms Microbiomes. 2021; 7(1):66. PMC: 8352958. DOI: 10.1038/s41522-021-00235-2. View

5.
Peng X, Zhao Y, Lin T, Shu X, Hou L, Gao L . [Research of relationship between frailty and gut microbiota on middle-aged and the aged patients with diabetes]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2021; 38(6):1126-1133. PMC: 9927114. DOI: 10.7507/1001-5515.202101083. View